Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Fusion protein with reinforced erythrocytin activity in vivo

A fusion protein and generative technology, applied in the field of fusion proteins, can solve the problems of difficult to obtain target protein, reduction, loss of protein intrinsic activity, etc.

Inactive Publication Date: 2003-06-04
CJ HEALTHCARE CORP
View PDF0 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

That is, in most cases, the target protein is not easily obtained without professional skills, on the contrary, the inherent activity of the protein can be reduced or lost by adding or substituting new amino acids

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Fusion protein with reinforced erythrocytin activity in vivo
  • Fusion protein with reinforced erythrocytin activity in vivo
  • Fusion protein with reinforced erythrocytin activity in vivo

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0056] Example 1: Gene preparation

[0057] Using 50 pmol each of primers EP1 and EP2 complementary to the end of EPO cDNA, conventional PCR (PCR PreMix kit from Bioneer Company) was performed from a human-derived fetal liver cDNA library (Invitrogen Company) to obtain EPO cDNA. TPO cDNA was obtained in the same manner using primers T1 and T2 complementary to the ends of TPO cDNA. A total of 30 cycles of PCR were performed using the high-fidelity Taq system of BM Company. The reaction conditions were annealing at 52°C for 40 seconds, extension at 72°C for 55 seconds and denaturation at 94°C for 20 seconds to generate EPO cDNA and TPO cDNA. They were respectively cloned into the cloning vector pGEM-T (Promega Company). That is, the PCR product was eluted from 1% agarose gel, ligated to pGEM-T, and introduced into E. coli NM522. Transformed E. coli were grown overnight on LB-ampicillin plates containing X-gal / IPTG. Plasmids were purified from white colonies and treated with ...

Embodiment 2

[0063] Invitrogen's pcDNA3-1 vector was used as the expression vector. The ELTP and ESTP genes cloned into the pGEM-T vector contain HindIII and BamHI recognition sites at the ends, respectively. pcDNA3.1, pGEM-ELTP and pGEM-ESTP were treated with restriction enzymes HindIII and BamHI, respectively. Linear pcDNA3.1, ELTP and ESTP genes were isolated on agarose gels using Qiagen extraction kits. After pcDNA3.1 was ligated with ELTP or ESTP, the ligated product was introduced into E.coli NM522. Plasmids were isolated from colonies of transformed E. coli grown overnight on LB-ampicillin plates and treated with restriction enzymes HindIII and BamHI. Colonies containing ELTP or ESTP genes were then screened out by 1% agarose gel electrophoresis. These plasmids were named pcDNA-ELTP and pcDNA-ESTP respectively (Fig. 3). Example 3: Transformation and expression of CHO cells

Embodiment 3

[0064]CHO cells (DG44) were cultured in 60mm cell culture dishes to 40-80% confluence (1-4×105 cells / 60mm dish). Mix 3 μl of superfection reagent (BM company) and 97 μl of cell culture medium (α-MEM with matrix, no serum, no antibody), and then add plasmid pcDNA-ELTP (=0.1 μg / μl, about 2 μg) and the vector pLTRdhfr26 (ATCC37295, 0.2 µg) having the dhfr gene. The mixture was reacted at room temperature for 5-10 minutes, and then added to the cells prepared above. One day later, the original medium was renewed with G418-containing medium (matrix-free α-MEM, 10% FBS) at a content of 500 μg / ml. The medium was then continuously refreshed with medium containing 500 μg / ml G418 for 7-10 days, during which time the cells without the G418 resistance gene and the negative control cells were completely killed. The screened cells were fully cultured on G418 medium, and the expressed ELTP protein was identified with the EPO ELISA kit of BM Company. The same method was applied to pcDNA-ES...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A fusion protein (I), where a carboxy terminal peptide (CTP) of thrombopoietin (TPO) is fused with the carboxy terminal of human erythropoietin (EPO), is new. Independent claims are also included for the following: (1) nucleic acid (II) encoding (I); and (2) preparing (I). - ACTIVITY : Antianemic. No biological data is given. - MECHANISM OF ACTION : Stimulator of production and differentiation of red blood cells.

Description

technical field [0001] The invention relates to a fusion protein capable of enhancing the in vivo activity of erythropoietin (hereinafter referred to as EPO), and the EPO is a new drug for treating anemia. Specifically, the present invention relates to a fusion protein with highly enhanced in vivo half-life and activity of erythropoietin by fusing the EPO molecule with a certain peptide that has half-life-extending activity and is derived from the human body. Background technique [0002] EPO is a glycoprotein with a molecular weight of 30,000-34,000. It is a factor that promotes red blood cell production and differentiation. Binding of the protein to receptors on erythroid precursor cells results in decreased intracellular calcium ion concentration, increased DNA biosynthesis, and stimulates hemoglobin formation, among others. The EPO can be used to treat renal failure anemia, premature infant anemia, hypothyroid anemia, malnutrition anemia and the like. The clinical use ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N15/02A61K38/18A61P7/06C07K7/08C07K14/505C07K14/52C07K19/00C12N15/12C12N15/62C12P21/02
CPCC07K14/505C07K2319/00A61K38/00C07K14/524A61P7/06C07K19/00
Inventor 李东亿吴明锡郑普燮朴持淑金起完
Owner CJ HEALTHCARE CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com